Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 6/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.39 |
| ▸ | PRKCG | P05129 | 1/20 | 0.39 |
| ▸ | PRKCB | P05771 | 1/20 | 0.39 |
| ▸ | PRKCA | P17252 | 1/20 | 0.39 |
| ▸ | PRKCH | P24723 | 1/20 | 0.39 |
| ▸ | PRKCI | P41743 | 1/20 | 0.39 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.39 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.39 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.39 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.39 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1658870 | 0.95 | ACE2 (0.47) | ACE2LMNASPHK1OPRM1GPR84 | |
| SCHEMBL1659105 | 0.93 | SPHK1 (0.50) | ACE2LMNASPHK1OPRM1GPR84 | |
| SCHEMBL5583724 | 0.93 | SPHK1 (0.50) | ACE2LMNASPHK1OPRM1GPR84 | |
| SCHEMBL13900820 | 0.93 | ACE2 (0.41) | ACE2LMNASPHK1PRKD3PRKCG | |
| SCHEMBL5684704 | 0.93 | SPHK1 (0.50) | ACE2LMNASPHK1OPRM1GPR84 | |
| SCHEMBL5687214 | 0.93 | SPHK1 (0.50) | ACE2LMNASPHK1OPRM1GPR84 | |
| SCHEMBL5583762 | 0.93 | SPHK1 (0.50) | ACE2LMNASPHK1OPRM1GPR84 | |
| SCHEMBL5687474 | 0.93 | SPHK1 (0.50) | ACE2LMNASPHK1OPRM1GPR84 | |
| SCHEMBL1658455 | 0.88 | ACE2 (0.39) | ACE2SPHK1OPRM1MAPT | |
| SCHEMBL5583601 | 0.84 | ACE2 (0.55) | ACE2LMNASPHK1OPRM1GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039638-A1 | Asymmetric Hydrogenation of Alkennes Using Chiral Iridium Complexes | DSM IP ASSETS B.V. (NL) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039638-A1 | Asymmetric Hydrogenation of Alkennes Using Chiral Iridium Complexes | SQLE, FADS1, FADS2 | ACE2 710/4885LMNA 4536/4885SPHK1 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.